Summary & Overview

CPT 0496U: ColoScape Plus Blood Test for Colorectal Cancer Risk

CPT code 0496U identifies a Proprietary Laboratory Analyses (PLA) test: ColoScape™ Plus from DiaCarta Inc., a blood-based assay that uses RT–PCR and ELISA to evaluate cell-free DNA and protein markers for colorectal cancer or advanced adenoma risk. As a PLA code, 0496U is unique to a single manufacturer's commercial test and signals clinical use of proprietary molecular diagnostics in cancer screening and risk stratification. Nationally, PLA codes like 0496U matter because they affect payer coverage decisions, coding consistency, and access to emerging diagnostics.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, the service context for billing and claims, and what to expect in payer coverage conversations. The publication summarizes common modifiers associated with the code, outlines typical sites of service, and highlights the implications of PLA designation for coding and reimbursement processes. It also provides context on clinical utility for colorectal cancer risk assessment and how proprietary lab tests are captured in billing systems.

Data not provided in the input are identified explicitly where relevant (for example, associated taxonomies, specific ICD-10 diagnosis mappings, and related codes).

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0496UCPTProprietary Laboratory Analysesmolecular diagnosticscolorectal cancerblood-based testingRT-PCRELISA

Billing Code Overview

CPT code 0496U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the ColoScape™ Plus test from DiaCarta Inc. The assay combines real–time reverse transcription polymerase chain reaction (RT–PCR) and enzyme–linked immunosorbent assay (ELISA) to analyze cell–free DNA and proteins in blood, providing an assessment of the risk for colorectal cancer or advanced adenoma.

Service type: Proprietary laboratory test using molecular and protein analysis to assess colorectal cancer risk

Typical site of service: Clinical laboratory or diagnostic testing facility (blood-based testing, phlebotomy performed in outpatient settings)

Clinical & Coding Specifications

Clinical Context

A typical patient is a 50–to–75‑year‑old adult with average to elevated risk for colorectal neoplasia who declines or is unable to undergo colonoscopy, or as an adjunct to screening when noninvasive blood‑based testing is selected. The clinician (gastroenterologist, primary care physician, or oncologist) orders the ColoScape™ Plus test (0496U) when evaluation of circulating cell‑free DNA mutations and protein biomarkers is desired to estimate risk of colorectal cancer or advanced adenoma. The clinical workflow: the patient presents to an outpatient phlebotomy site or clinical laboratory for venipuncture; a laboratory requisition specifying test 0496U is completed and the blood specimen is collected, processed, and shipped per the manufacturer's instructions; the laboratory performs RT‑PCR and ELISA analyses on cell‑free DNA and proteins; a consolidated report with risk stratification is generated and returned to the ordering provider; the clinician reviews results with the patient to determine need for diagnostic colonoscopy or intensified surveillance. Typical site of service is outpatient laboratory, physician office with phlebotomy, or ambulatory surgical center coordinating follow‑up colonoscopy if indicated. Common patient scenarios include: surveillance in patients with prior adenoma, evaluation of occult symptoms (unexplained iron deficiency anemia or rectal bleeding), or alternative screening for patients refusing colonoscopy.

Coding Specifications

Modifier	Description	When to Use
`00`

Taxonomy Code	Specialty	Notes
`207RG0100X`	Gastroenterology	Ordering and follow‑up for colorectal cancer risk assessment and referral for colonoscopy.
`207Q00000X`	Family Medicine	Primary care providers ordering noninvasive screening alternatives and coordinating screening programs.
`208000000X`	Internal Medicine	Internists managing screening, anemia evaluation, or symptom workup who order blood‑based tests.
`363L00000X`	Laboratory – Clinical Chemistry	Performing laboratory specialty responsible for technical RT‑PCR and ELISA testing and reporting.
`2084P0800X`	Hematology/Oncology	Oncology specialists ordering assay for risk stratification or surveillance in high‑risk patients.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R19.5`	Other fecal abnormalities	May prompt noninvasive blood testing for colorectal pathology when stool testing is inconclusive or not performed.

| K92.1 | Melena | Symptom that can lead to ordering noninvasive tests including blood‑based assays to assess for colorectal neoplasia when endoscopy is delayed. |

| D50.9 | Iron deficiency anemia, unspecified | Unexplained iron deficiency anemia in adults often triggers evaluation for occult gastrointestinal bleeding and colorectal cancer screening using blood‑based adjunct tests. |

| Z12.11 | Encounter for screening for malignant neoplasm of colon | Appropriate code when the test is ordered as a screening modality for colorectal cancer risk assessment. |

| Z86.010 | Personal history of colonic polyps | Surveillance context where blood‑based testing may be used as an adjunct between colonoscopies or when colonoscopy is deferred. |

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0496U`	ColoScape™ Plus — RT‑PCR and ELISA analysis of cell‑free DNA and proteins for colorectal cancer/advanced adenoma risk (Proprietary Laboratory Analyses)	The specific PLA test code for the ColoScape™ Plus assay; use this code to report the combined molecular and protein blood test.

| 83520 | Drug assay, qualitative; each procedure | Used if reflex testing for specific circulating protein targets or ancillary qualitative assays are billed separately by the performing lab when payer requires itemization. |

| 81479 | Unlisted molecular pathology procedure | Used when additional molecular analyses performed by the lab are not otherwise described by a specific CPT PLA or molecular pathology code and require unlisted reporting. |

| 81162 | BRCA1 and BRCA2 analysis, if applicable — or other targeted gene analysis codes | Used in settings where broader hereditary panels or targeted DNA mutation analyses are performed in parallel; may be relevant when ordering genetic risk panels alongside 0496U. |

| 80061 | Lipid panel | Used commonly in the same outpatient visit for general cancer risk assessment and preventive health panels, though not directly part of the assay. |